American Heart Association

CHICAGO — Analysis of a potential link between use of calcium channel blockers and risk for breast cancer yielded conflicting results in two separate cohorts, according to results presented at the American Heart Association Scientific Sessions.

CHICAGO — Monthly hospitalizations for acute aortic dissection were increased during the peak influenza season from November to March, according to data reported at the American Heart Association Scientific Sessions.

The number of patients presenting to EDs for STEMI decreased from 2006 to 2011 across all age groups and regions in the United States, according to data presented at the American Heart Association Scientific Sessions.

CHICAGO — Andexanet alfa safely and effectively reversed the anticoagulant effects of apixaban among older patients, according to data presented at the American Heart Association Scientific Sessions.

CHICAGO — Beta-blocker use at discharge in patients with stable angina without prior history of MI or systolic HF undergoing elective PCI did not affect mortality at 30 days or 3 years, according to findings presented at the American Heart Association Scientific Sessions.

CHICAGO — A coordinated response between emergency medical personnel and hospital staff was associated with faster care and improved survival in patients with STEMI, researchers reported at the American Heart Association Scientific Sessions.

CHICAGO — Pregnant women with congenital heart disease had a low rate of congestive HF and arrhythmias during hospitalization and no greater risk for in-hospital mortality and cardiac arrest than women without congenital heart disease, according to data presented at the American Heart Association Scientific Sessions.

CHICAGO — In a retrospective analysis conducted by the US Department of Defense, dabigatran was favorable to warfarin for stroke and major bleeding outcomes, according to findings presented at the American Heart Association Scientific Sessions.

CHICAGO — Disruptive innovations are in the process of changing how CV research is conducted, which could potentially deliver better treatments to patients more quickly, American Heart Association President Elliott Antman, MD, FAHA, said during a keynote address at the AHA Scientific Sessions.

A remaining question is whether IMPROVE-IT is relevant to clinical practice a decade later. We think the answer is definitely yes.